The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose

Molecular Carcinogenesis

Volumn 46, Issue 3, 2007, Pages 242-248

  Takahashi, Keiko ^a,b   Eguchi, Hidetaka ^a   Arihiro, Koji ^c   Ito, Reiko ^a   Koyama, Kojiro ^a,e   Soda, Midori ^a   Cologne, John ^a   Hayashi, Yuzo ^d   Nakata, Yoshihiro ^b   Nakachi, Kei ^a   Hamatani, Kiyohiro ^a  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^d HIROSHIMA CITY ASA HOSPITAL   (Japan)

^e Oumu Municipal National Health Insurance Hospital   (Japan)

Author keywords

BRAFV600E mutation; Latency period; Radiation dose; Thyroid carcinogenesis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; ATOMIC BOMB; BRAF GENE; CANCER PATIENT; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; PTC GENE; RADIATION DOSE; RADIATION EXPOSURE; RET GENE; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WARFARE; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION DOSAGE; SURVIVORS; THYROID NEOPLASMS;

EID: 33947095518     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20277     Document Type: Article

References (39)

1. Thompson DE, Mabuchi K, Ron E, et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 1994;137:S17-S67.
2. Astakhova LN, Anspaugh LR, Beebe GW, et al. Chernobyl-related thyroid cancer in children of Belarus: A case-control study. Radiat Res 1998;150:349-356.
3. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
4. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathologenesisof PTC. Oncogene 2003;22:4578-4580.
5. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-7440.
6. Dibb NJ, Dilworth SM, Mol CD. Switching on kinase: Oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 2004;4:718-727.
7. Davies H, Bignell G, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
8. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-262.
9. Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
10. T1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004;25:1729-1735.
11. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005;65:4238-4245.
12. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88: 5399-5404.
13. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv 2005;446:589-595.
14. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63:4561-4567.
15. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 2004; 61:239-243.
16. Kim K-H, Kang D-W, Kim S-H, Seng IO, Kang D-Y. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-821.
17. V599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-2420.
18. Koinuma K, Shitoh K, Miyakura Y, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 2004;108: 237-242.
19. T1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280-4284.
20. Lima J, Trovisco V, Soares P, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4267-4271.
21. Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004; 209:1-6.
22. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005;115:94-101.
23. Powell N, Jeremiah S, Morishita M, et al. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 2005;205:558-564.
24. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: A commentary on the second edition. Cancer 1989;63:908-911.
25. Preston DL, Pierce DA, Shimizu Y, et al. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res 2004;162:377-389.
26. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6: 292-306.
27. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
28. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22: 6455-6457.
29. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9:6483-6488.
30. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-486.
31. Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997;15:1263-1273.
32. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ref oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997; 57:1690-1694.
33. Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: Biological, phenotypic, and clinical implications. Clin Cancer Res 2000; 6:1093-1103.
34. Mitsutake N, Miyagishi M, Mitsutake S, et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: Functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endcrinology 2006;147:1014-101.9.
35. Ouyang B, Knauf J, Smith E, et al. Inhibitors of RAF kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006;12: 1785-1793.
36. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-1081.
37. Ito T, Seyama T, Iwamoto KS, et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 1993;53: 2940-2943.
38. Mizuno T, Kyoizumi S, Suzuki T, et al. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 1997;15:1455-1460.
39. Mizuno T, Iwamoto KS, Kyoizumi S, et al. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 2000;19:438-443.